{"id":"atomoxetine-ato","safety":{"commonSideEffects":[{"rate":"16-22%","effect":"Decreased appetite"},{"rate":"7-26%","effect":"Nausea"},{"rate":"2-8%","effect":"Dizziness"},{"rate":"3-16%","effect":"Fatigue"},{"rate":"9-21%","effect":"Insomnia"},{"rate":"7-19%","effect":"Headache"},{"rate":"7-16%","effect":"Abdominal pain"},{"rate":"2-6%","effect":"Mood swings / irritability"},{"rate":"variable","effect":"Increased blood pressure"},{"rate":"variable","effect":"Increased heart rate"}]},"_chembl":{"chemblId":"CHEMBL1702","moleculeType":"Small molecule","molecularWeight":"291.82"},"_dailymed":{"setId":"14f2804d-2914-4dd9-86c0-d084fcfd7e50","title":"ATOMOXETINE (ATOMOXETINE) CAPSULE [NORTHSTAR RXLLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) that blocks the norepinephrine transporter, preventing the reabsorption of norepinephrine from the synaptic cleft. This increases norepinephrine concentration in key brain regions involved in attention and executive function. Unlike stimulant medications, it does not directly release norepinephrine or dopamine and has minimal abuse potential.","oneSentence":"Atomoxetine selectively inhibits the reuptake of norepinephrine in the central nervous system, increasing norepinephrine availability at synapses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:28.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults"},{"name":"ADHD-related symptoms in patients with comorbid conditions"}]},"trialDetails":[{"nctId":"NCT07280468","phase":"PHASE4","title":"Endotype DIrected Treatment for OSA in Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2026-02-01","conditions":"Obstructive Sleep Apnea (OSA), Down Syndrome","enrollment":200},{"nctId":"NCT04115878","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea In Children With Down Syndrome","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2020-10-21","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":22},{"nctId":"NCT04113551","phase":"","title":"A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":17418},{"nctId":"NCT05933603","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-09-29","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atomoxetine (ATO)","genericName":"Atomoxetine (ATO)","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atomoxetine selectively inhibits the reuptake of norepinephrine in the central nervous system, increasing norepinephrine availability at synapses. Used for Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults, ADHD-related symptoms in patients with comorbid conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}